MetLife Investment Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

MetLife Investment Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-5,468	Closed	-$86.2K	–	2876
2023 Q3	$86.2K	Hold	5,468	–	–	﹤0.01%	2654
2023 Q2	$106K	Hold	5,468	–	–	﹤0.01%	2642
2023 Q1	$155K	Hold	5,468	–	–	﹤0.01%	2367
2022 Q4	$160K	Hold	5,468	–	–	﹤0.01%	2383
2022 Q3	$144K	Hold	5,468	–	–	﹤0.01%	2483
2022 Q2	$243K	Sell	5,468 -2,297	-30%	-$106K	﹤0.01%	2179
2022 Q1	$384K	Buy	7,765 +2,777	+56%	+$133K	﹤0.01%	1944
2021 Q4	$254K	Hold	4,988	–	–	﹤0.01%	1912
2021 Q3	$278K	Hold	4,988	–	–	﹤0.01%	1869
2021 Q2	$213K	Hold	4,988	–	–	﹤0.01%	2130
2021 Q1	$208K	Hold	4,988	–	–	﹤0.01%	2033
2020 Q4	$232K	Hold	4,988	–	–	﹤0.01%	1900
2020 Q3	$212K	Hold	4,988	–	–	﹤0.01%	1835
2020 Q2	$239K	Hold	4,988	–	–	﹤0.01%	1794
2020 Q1	$229K	Hold	4,988	–	–	﹤0.01%	1621
2019 Q4	$300K	Hold	4,988	–	–	﹤0.01%	1750
2019 Q3	$282K	Hold	4,988	–	–	﹤0.01%	1742
2019 Q2	$278K	Hold	4,988	–	–	﹤0.01%	1835
2019 Q1	$252K	Hold	4,988	–	–	﹤0.01%	1849
2018 Q4	$201K	Hold	4,988	–	–	﹤0.01%	1903
2018 Q3	$346K	Hold	4,988	–	–	﹤0.01%	1766
2018 Q2	$377K	Buy	4,988 +915	+22%	+$57.6K	﹤0.01%	1586
2018 Q1	$215K	Hold	4,073	–	–	﹤0.01%	1849
2017 Q4	$218K	Buy	+4,073	New	+$227K	﹤0.01%	1880

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

MetLife Investment Management's EGRX Position: Q4 2023 in Review

MetLife Investment Management sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2023, closing a stake of 5,468 shares — an estimated $86.2K sold.

MetLife Investment Management first reported a position in EGRX in Q4 2017 and held it in 24 quarters. The position peaked at $384K in Q1 2022. 104 funds tracked by Wall St. Rank hold EGRX as of Q4 2023.

MetLife Investment Management reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
MetLife Investment Management sold 5,468 Eagle Pharmaceuticals, Inc. shares in Q4 2023, an estimated $86.2K.
MetLife Investment Management first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2017 and held it in 24 quarters.
MetLife Investment Management's Eagle Pharmaceuticals, Inc. position peaked at $384K in Q1 2022.
104 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2023.

Based on MetLife Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.